In Japan, the incidence of cardiogenic cerebral infarction caused by atrial fibrillation has been increasing rapidly. The major risk factor for the occurrence of cerebral infarction is age, but factors associated with the development of atrial fibrillation also play an important role, such as a history of cardiac failure, hypertension, diabetes, and cerebral infarction. Prophylactic therapy that inhibits the onset of atrial fibrillation itself, rather than symptomatic treatment after the onset of fibrillation, is important for the prevention of cardiogenic cerebral infarction. ARBs and renin-angiotensin receptor blockers are reported to be useful agents for prophylactic therapy. In addition to its antihypertensive effect, the ARB candesartan may suppress the development of atrial fibrillation. Large-scale clinical studies have shown that treatment with candesartan can prevent the occurrence of stroke. Management of high blood pressure is an essential part of the treatment of stroke, and it is particularly important in the acute phase when autoregulation of the cerebral circulation is impaired. Treatment with warfarin, as well as ARBs and statins (to improve endothelial function), is useful for preventing the recurrence of cardiogenic cerebral infarction. In particular, the ARB candesartan is very useful because of its additional protective effect on cognitive function.
|Number of pages||7|
|Journal||Japanese Pharmacology and Therapeutics|
|Publication status||Published - 2005 Dec 1|
ASJC Scopus subject areas
- Pharmacology (medical)